HealthTrust and Heartland Information Services sign three-year agreement

Heartland Information Services, a national provider of medical transcription services, has signed a new three-year agreement with HealthTrust Purchasing Group (HealthTrust), one of the nation's leading health care group purchasing organizations. The agreement covers dictation, transcription and document delivery services.

"Through this agreement, HealthTrust members will have access to customizable technical solutions that can provide significant cost savings and other financial advantages. This comes at a time when it's crucial for health systems and hospitals to cut costs without sacrificing patient care," said Jerry Cirino, president and chief executive officer of Heartland.

As a provider of transcription services, Heartland offers HealthTrust members a single, fully integrated platform that can interface with virtually any facility's existing technology platform. This includes Heartland's GEMSTAR(TM) dictation and transcription system and Tracker Plus(TM) document delivery and reporting system. These systems allow users to track a document in real time from dictation through delivery. Heartland currently serves more than 50 HealthTrust facilities.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers uncover the potential of JAK inhibitors to treat life-threatening skin disease